News

  • Reset
Capsules

Generic ABSORICA® added to US portfolio

29 Sep 2021

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of isotretinoin capsules, 10 mg, 20 mg, 30 mg and 40 mg in the United States.

Learn more

Woman's Hands With Foam

FDA Approves Lexette® for Adolescent Plaque Psoriasis

22 Sep 2021

Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents.

Learn more

Financial,Data,Graph,Chart,,Vector,Illustration.,Abstract,Background,With,Graph

2021 Full Year Results Media Release

27 Aug 2021

2021 Full Year Results Media Release

Learn more

Frank Condella

Mayne Pharma Board Renewal and New Chairman

26 Aug 2021

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr Frank Condella, a US resident, will be appointed Chairman with effect from 30 September 2021.

Learn more

Law,Books,And,Scales,Of,Justice,On,Desk,In,Library

Class action proceeding

3 Aug 2021

Mayne Pharma Group Limited (ASX: MYX) has been served with a class action proceeding against Mayne Pharma in the Supreme Court of Victoria.

Learn more

Female looking into mirror

Mayne Pharma expands Australian dermatology portfolio

21 Jun 2021

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has licensed the Australian rights to SOLARAZE®

Learn more

Contraceptive Packet

Nextstellis® Oral Contraceptive Now Available in the United States

21 Jun 2021

US commercial launch of NEXTSTELLIS® a new oral contraceptive with a novel estrogen.

Learn more

Contraceptive Packet

Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published

27 May 2021

NEXTSTELLIS® has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA)

Learn more

Contraceptive Packet

FDA approval of novel oral contraceptive NEXTSTELLIS®

16 Apr 2021

US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive NEXTSTELLIS®

Learn more